REGN logo

Regeneron Pharmaceuticals, Inc.

REGN
Healthcare|Biotechnology|US
$904.35
+1.45 (+0.16%)
DCF Value
$2028.80
Tangible Book / Share
$316.45
Graham Number
$592.50
Cash / Share
$91.46

Analyst Consensus

Buy49 analysts
Strong Buy
0
Buy
34
Hold
15
Sell
0
Strong Sell
0
Consensus Target
$887.79
Implied Upside
-1.8%
Low Target
$756.00
High Target
$1100.00

Price Target Trend

Last Month
$964.71
7 targets · +7% vs price
Last Quarter
$896.06
17 targets · -1% vs price
Last Year
$851.03
68 targets · -6% vs price
All Time
$867.69
159 targets · -4% vs price

Rating Trend

Dec 25
19 buy · 8 hold · 1 sell
Jan 26
20 buy · 8 hold · 1 sell
Feb 26
19 buy · 8 hold · 0 sell
Mar 26
22 buy · 8 hold · 0 sell
Apr 26
22 buy · 7 hold · 0 sell
May 26
23 buy · 8 hold · 0 sell
Jun 26
21 buy · 8 hold · 0 sell
Jul 26
21 buy · 10 hold · 0 sell
Aug 26
18 buy · 10 hold · 1 sell
Sep 26
18 buy · 9 hold · 1 sell
Oct 26
19 buy · 9 hold · 1 sell
Nov 26
19 buy · 9 hold · 1 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 2, 2026Cantor FitzgeraldCarter Gould$980.00(+2%)$962.36StreetInsider
Nov 2, 2026Wells Fargo$1030.00(+11%)$927.89StreetInsider
Nov 2, 2026GuggenheimYatin Suneja$1100.00(+19%)$927.89StreetInsider
Nov 2, 2026Wells FargoMohit Bansal$925.00(-0%)$927.89StreetInsider
Oct 30, 2026Robert W. BairdBrian Skorney$875.00(-6%)$927.89StreetInsider
Oct 19, 2026Piper Sandler$865.00(+9%)$790.74TheFly
Oct 14, 2026UBS$978.00(+26%)$778.36TheFly
Oct 8, 2026RBC CapitalBrian Abrahams$810.00(+11%)$730.08TheFly
Oct 8, 2026Raymond JamesChris Raymond$911.00(+23%)$742.12StreetInsider
Oct 7, 2026Truist Financial$780.00(+4%)$747.51TheFly
Oct 7, 2026Morgan Stanley$779.00(+5%)$743.60TheFly
Oct 1, 2026Jefferies$930.00(+25%)$741.16TheFly
Oct 1, 2026BMO CapitalEvan David Seigerman$920.00(+24%)$741.41StreetInsider
Oct 1, 2026Argus Research$850.00(+12%)$758.27TheFly
Sep 10, 2026HSBCRajesh Kumar$920.00(+14%)$807.65TheFly
Aug 17, 2026Leerink PartnersDavid Risinger$824.00(+3%)$803.48TheFly
Aug 14, 2026BernsteinJeffrey Walch$756.00(-5%)$799.46StreetInsider
Aug 3, 2026Guggenheim$1030.00(+35%)$763.51TheFly
Jul 31, 2026RBC Capital$737.00(-0%)$739.50TheFly
Jul 31, 2026Morgan Stanley$758.00(+3%)$738.82TheFly

Recent Rating Actions

FirmActionRatingDate
B of A SecuritiesmaintainBuyNov 2, 2026
Leerink PartnersmaintainMarket PerformNov 2, 2026
BernsteinmaintainMarket PerformNov 2, 2026
Morgan StanleymaintainEqual WeightNov 2, 2026
Truist SecuritiesmaintainBuyNov 2, 2026
RBC CapitalmaintainSector PerformNov 2, 2026
GuggenheimmaintainBuyNov 2, 2026
Wells FargomaintainEqual WeightNov 2, 2026
Evercore ISI GroupmaintainOutperformNov 2, 2026
Canaccord GenuitymaintainBuyNov 2, 2026
Cantor FitzgeraldmaintainOverweightNov 2, 2026
BairdmaintainNeutralNov 2, 2026
CitigroupmaintainNeutralOct 30, 2026
JP MorganmaintainOverweightOct 30, 2026
Canaccord GenuitymaintainBuyOct 28, 2026
TD CowenmaintainBuyOct 21, 2026
Piper SandlermaintainOverweightOct 19, 2026
UBSupgradeNeutral →BuyOct 15, 2026
RBC CapitalmaintainSector PerformOct 8, 2026
Morgan StanleymaintainEqual WeightOct 7, 2026
Truist SecuritiesmaintainBuyOct 7, 2026
JP MorganmaintainOverweightOct 6, 2026
Argus ResearchupgradeHold →BuyOct 1, 2026
JefferiesmaintainBuyOct 1, 2026
RBC CapitalmaintainSector PerformSep 29, 2026

Earnings History

Next report: Jan 28, 2027 · EPS est. $25.39
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 30, 2026$20.07$16.51$5.12B$4.58B
Jul 30, 2026$14.29$10.16$4.29B$3.82B
Apr 29, 2026$9.47$8.91$3.61B$3.48B
Jan 30, 2026$11.44$10.74$3.88B$3.81B
Oct 28, 2025$11.83$9.65$3.75B$3.59B
Aug 1, 2025$12.89$8.43$3.68B$3.29B
Apr 29, 2025$8.22$8.62$3.03B$3.25B
Feb 4, 2025$12.07$11.21$3.79B$3.74B

News

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation

These are among the best the industry has to offer.

Nov 8, 2026fool.com
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD

Single administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks

Nov 8, 2026globenewswire.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock: Insider Huda Zoghbi Sells 7,439 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) Director Huda Zoghbi sold 7,439 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $970.46, for a total value of $7,219,251.94. Following the completion of the transaction, the director owned 1,703 shares in the company,

Nov 7, 2026defenseworld.net
Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Sells $4,311,878.34 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) EVP Joseph Larosa sold 4,466 shares of the firm's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the transaction, the executive vice president owned 38,906 shares of

Nov 7, 2026defenseworld.net
Regeneron Pharmaceuticals, Inc. $REGN Stock Purchased by Compass Financial Management LLC

Compass Financial Management LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 4,526.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,007 shares of the biopharmaceutical company's stock after acquiring an additional 2,942 shares during the

Nov 5, 2026defenseworld.net
Regeneron Pharmaceuticals, Inc. $REGN Stock: AIA Group Ltd Decreases Holdings

AIA Group Ltd cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 37.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,482 shares of the biopharmaceutical company's stock after selling 3,254 shares during the period. AIA Group Ltd's holdings

Nov 5, 2026defenseworld.net
Regeneron Pharmaceuticals, Inc. $REGN Stock: Bank Julius Baer & Co. Ltd Zurich Raises Stake

Bank Julius Baer and Co. Ltd Zurich boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 165.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,904 shares of the biopharmaceutical company's stock after

Nov 5, 2026defenseworld.net
Why Regeneron (REGN) Might be Well Poised for a Surge

Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Nov 4, 2026zacks.com
REGN vs. ILMN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

Nov 4, 2026zacks.com
UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked Cleveland-Cliffs Inc. (NYSE:CLF).

Nov 3, 2026benzinga.com
3,572 Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 356.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,573 shares of the biopharmaceutical company's stock after purchasing an additional 3,572 shares during the period.

Nov 3, 2026defenseworld.net
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m.

Nov 2, 2026globenewswire.com
These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported better-than-expected third-quarter 2026 results. Regeneron reported adjusted earnings of $20.07 per share, up 70% year over year and above the analyst consensus estimate of $16.19.

Nov 2, 2026benzinga.com
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Nov 2, 2026benzinga.com
Critical Review: Syndax Pharmaceuticals (NASDAQ:SNDX) vs. Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ: REGN - Get Free Report) and Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Earnings and Valuation This table compares Regeneron Pharmaceuticals

Nov 2, 2026defenseworld.net
Regeneron: 3 Key Takeaways for Long-Term Investors

Dupixent global quarterly net sales grew 35% year over year to $6.5 billion. Total revenue increased 36% year over year to $5.1 billion.

Oct 31, 2026fool.com
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up

Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.

Oct 30, 2026zacks.com
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript

Oct 30, 2026seekingalpha.com
Regeneron Is Just Getting Started

Regeneron delivered a standout Q3, with net sales up 36% year-over-year to $5.1 billion, driven mainly by Dupixent's outperformance. Eylea HD and Libtayo posted strong growth, while Eylea 2 mg showed resilience despite biosimilar competition; pipeline updates further reinforced Regeneron's momentum. I now expect 2026 revenues to reach $19 billion, a 33% increase, and non-GAAP EPS growth in the low- to mid-50% range.

Oct 30, 2026seekingalpha.com
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call

Regeneron Pharmaceuticals NASDAQ: REGN reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT, EYLEA HD and LIBTAYO.

Oct 30, 2026marketbeat.com